11/15/2007 | SS | PerkinElmer acquires ViaCell
|
11/9/2007 | SS | PerkinElmer completes offer for ViaCell
|
10/25/2007 | SS | PerkinElmer clears waiting period hurdle in tender for ViaCell
|
10/12/2007 | SS | PerkinElmer subsidiary starts cash tender offer for ViaCell
|
11/8/2006 | BT | Market Commentary: Catalyst higher on debut; Hollis-Eden off 19% on PIPE; stem cell names better; Trimeris rises 23%
|
11/2/2006 | BT | ViaCell: sales of ViaCord product up 25%
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
6/26/2006 | BT | FDA conditionally approves ViaCell's IDE to evaluate fertility treatment
|
6/13/2006 | BT | ViaCell to collaborate with Centocor on using stem cells to treat cardiac disease
|
5/30/2006 | BT | ViaCell: Patent office rejects PharmaStem patent claims
|
4/25/2006 | BT | ViaCell, Pall get FDA clearance for sterile bag to store cord blood
|
3/14/2006 | BT | Credit Suisse reiterates ViaCell at outperform
|
3/13/2006 | BT | ViaCell's stem cells may regenerate damaged heart tissue, animal study shows
|
10/27/2005 | BT | ViaCell, Cord Blood settle marketing dispute
|
9/19/2005 | BT | Market Commentary: Viacell plunges on suspending study; StemCells rises on new filing; Inex drops on note demand
|
8/30/2005 | BT | Market Commentary: Amylin loses 3% after follow-on; Manhattan Pharma taps PIPEs; Momenta sold on news; ViaCell off
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|
6/20/2005 | BT | Market Commentary: HemoSense cuts IPO range; Impax labs, Xoma gain on credit fronts; ImClone up on drug plans
|